drugset / Trial / NCT00015626

A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)

NCT00015626

Phase 2 Completed 300 enrolled National Center for Research Resources (NCRR)
RandomizedDouble-blindTreatment

Summary

The goal of this study is to aggressively treat insulin resistance and its clinical manifestations when they first appear in childhood, and to prevent the subsequent progression towards impaired glucose tolerance and type-2 diabetes. In the process of this clinical trial, we will learn more about the early manifestations of insulin resistance, its treatment, and its relationship to obesity and type-2 diabetes through parallel in-vivo and in-vitro studies.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule
Subject Pioglitazone Small molecule
Subject Rosiglitazone Small molecule

Indications